Cartesian Therapeutics, Inc. ( (RNAC) ) has released its Q1 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering cell therapies for autoimmune diseases, leveraging proprietary technology to enhance cell function. The company recently released its earnings report for the first quarter of 2025, highlighting significant financial activities and changes. Cartesian Therapeutics reported a net loss of $17.7 million for the quarter, a notable improvement from the $56.8 million loss in the same period last year. The company’s revenue for the quarter was $1.1 million, primarily from collaboration and grant revenues, compared to $5.8 million in the previous year. Operating expenses increased to $23 million, driven by higher research and development costs. Looking ahead, Cartesian Therapeutics remains focused on advancing its product candidates through clinical development, with management expressing confidence in its ability to fund operations for at least the next 12 months.